KLP Kapitalforvaltning AS Makes New $299,000 Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

KLP Kapitalforvaltning AS purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 39,800 shares of the biotechnology company's stock, valued at approximately $299,000.

Several other hedge funds also recently added to or reduced their stakes in BCRX. Hillsdale Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 65,213.3% in the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock valued at $4,077,000 after buying an additional 541,270 shares in the last quarter. Principal Financial Group Inc. boosted its stake in BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after acquiring an additional 375,890 shares in the last quarter. Two Sigma Advisers LP boosted its stake in BioCryst Pharmaceuticals by 13.6% in the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company's stock valued at $16,576,000 after acquiring an additional 261,500 shares in the last quarter. Exome Asset Management LLC purchased a new position in shares of BioCryst Pharmaceuticals during the third quarter worth about $1,493,000. Finally, Franklin Resources Inc. increased its position in shares of BioCryst Pharmaceuticals by 177.8% during the third quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company's stock worth $1,968,000 after purchasing an additional 168,790 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

BCRX traded up $0.41 during trading on Friday, hitting $6.82. The stock had a trading volume of 3,113,466 shares, compared to its average volume of 2,805,137. The firm has a market capitalization of $1.43 billion, a P/E ratio of -11.18 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50. The company's 50-day moving average price is $7.96 and its 200 day moving average price is $7.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The firm's quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.28 earnings per share. As a group, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on BCRX shares. JMP Securities restated a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Wedbush assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $11.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.